Nordstjernan to invest in medtech company Ascilion
Nordstjernan is investing in Ascilion, a Swedish medtech company founded in 2012 and based in Stockholm, Sweden. Ascilion has developed and patented a technology that uses an array of hollow microneedles to extract the interstitial fluid (ISF) that surrounds the body’s cells and that is a good carrier of biomarkers. Ascilion’s technology has numerous fields of application, including within several branches of medical diagnostics. Nordstjernan will become the second largest owner in Ascilion and, as a partner to the company’s founder and current owners, the aim is to accelerate the company’s commercial development.
“We are impressed by Ascilion’s technology platform and by the team behind the company. Ascilion’s products are at the leading edge and can help develop and improve current diagnostic methods. Nordstjernan’s ambition is to continue growing in the health sector, and medtech and diagnostics are fields in which we want to actively invest. We look forward to supporting Ascilion in the company’s future development,” says Nordstjernan’s CEO Peter Hofvenstam.
“We are very pleased to welcome Nordstjernan as an owner. We look forward to working with Nordstjernan to transform Ascilion from a development company into a supplier of medtech products,” says Ascilion’s co-founder and CEO Markus Renlund.
In recent years, Nordstjernan has invested actively in the health sector, and its holdings in this sector currently account for nearly 25 percent of Nordstjernan’s net asset value.
The parties have agreed not to disclose the conditions of the transaction.
President and CEO
Questions will be answered by:
Peter Hofvenstam, CEO, Nordstjernan
Stefan Stern, Head of Communications, Nordstjernan
Telephone: +46 70 636 74 17
Nordstjernan is a family-controlled investment company whose business concept is to be an active owner that creates long-term value growth. More information about Nordstjernan can be found on www.nordstjernan.se.